Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET

Synapse

Volumn 36, Issue 1, 2000, Pages 57-65

  Nguyen, Tuong V ^a   Brownell, Anna Liisa ^a   Chen, Yin Ching Iris ^a   Livni, Elijahu ^a   Coyle, Joseph T ^a   Rosen, Bruce R ^a   Cavagna, Friedrich ^b   Jenkins, Bruce G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Bracco SpA   (Italy)

Author keywords

6 OHDA; Amphetamine; Apomorphine; CBV; CFT; Dopamine; fMRI; PET; Raclopride; Supersensitivity

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; AMPHETAMINE; APOMORPHINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; OXIDOPAMINE; RACLOPRIDE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN BLOOD VOLUME; CONTROLLED STUDY; CORPUS STRIATUM; FRONTAL CORTEX; HEMODYNAMICS; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; THALAMUS;

AMPHETAMINE; ANIMALS; APOMORPHINE; CEREBROVASCULAR CIRCULATION; COCAINE; DOPAMINE AGONISTS; DOPAMINE UPTAKE INHIBITORS; HEMODYNAMIC PROCESSES; MAGNETIC RESONANCE IMAGING; MALE; NEOSTRIATUM; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; ROTATION; STEREOTYPED BEHAVIOR; SYMPATHECTOMY, CHEMICAL; SYMPATHOLYTICS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034049332     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(200004)36:1<57::AID-SYN6>3.0.CO;2-K     Document Type: Article

References (49)

1. Alexander GE, Crutcher MD, DeLong MR. 1990. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 85:119-146.
2. Brownell GL, Burnham CA, Chesler DA. 1985. High resolution tomograph using analog coding. In: Greitz I, Ingver DH, Widen L, editors. The metabolism of the human brain studied with positron emission tomography. New York: Raven Press. p 13-19.
3. Brownell GL, Burnham CA, Sterns CW, Chesler DA, Brownell A-L, Palmer MR. 1989. Developments in high-resolution positron emission tomography at MGH. system and technology. 1.
4. Brownell AL, Elmaleh DR, Meltzer PC, Shoup TM, Brownell GL, Fischman AJ, Madras BK. 1996. Cocaine congeners as PET imaging probes for dopamine terminals. J Nucl Med 37:1186-1192.
5. Buchsbaum MS. 1992. Commentary on "the current status of PET scanning with respect to schizophrenia." Neuropsychopharmacology 7:67-68 (Discussion 73-65).
6. Cadet JL, Last R, Kostic V, Przedborski S, Jackson-Lewis V. 1991. Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen. Brain Res Bull 26:707-713.
7. Cannon WB, Rosenbluth A. 1949. The supersensitivity of denervated structures. New York: Macmillan.
8. Castellani S, Ellinwood EH Jr, Kilbey MM. 1978. Behavioral analysis of chronic cocaine intoxication in the cat. Biol Psychiatry 13:203-215.
9. Chen YI, Galpern WR, Brownell AL, Matthews RT, Bogdanov M, Isacson O, Beal MF, Rosen BR, Jenkins BG. 1997. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med 38:389-398.
10. Chesler DA. 1973. Positron emission tomography and three-dimensional reconstruction technique. In: Freedman GS, editor. Tomographic imaging in nuclear medicine. New York: Society of Nuclear Medicine. p 176-183.
11. Collier HO. 1968. Supersensitivity and dependence on cocaine. Nature 220:1327-1328.
12. Engber TM, Marin C, Susel Z, Chase TN. 1993. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding. Eur J Pharmacol 236:385-393.
13. Feuerstein C, Demenge P, Caron P, Barrette G, Guerin B, Mouchet P. 1981. Supersensitivity time course of dopamine antagonist binding after nigrostriatal denervation: evidence for early and drastic changes in the rat corpus striatum. Brain Res 226:221-234.
14. Head RJ, Hjelle JT, Jarrott B, Berkowitz B, Cardinale G, Spector S. 1980. Isolated brain microvessels: preparation, morphology, histamine andcatecholamine contents. Blood Vessels 17:173-186.
15. Heimer L, Zahm DS, Alheid GF. 1995. Basal ganglia. In: Paxinos G, editor. The rat nervous system. San Diego: Academic Press. p 579-628.
16. Hume SP, Opacka-Juffry J, Myers R, Ahier RG, Ashworth S, Brooks DJ, Lammertsma AA. 1995. Effect of L-dopa and 6-hydroxydopamine lesioning on [llC]raclopride binding in rat striatum, quantified using PET. Synapse 21:45-53.
17. Ingvar M, Lindvall O, Stenevi U. 1983. Apomorphine-induced changes in local cerebral blood flow in normal rats and after lesions of the dopaminergic nigrostriatal bundle. Brain Res 262:259-265.
18. Jones BE. 1982. Relationship between catecholamine neurons and cerebral blood vessels studied by their simultaneous fluorescent revelation in the rat brainstem. Brain Res Bull 9:33-44.
19. Kelly PH, Iversen SD. 1976. Selective 6-OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol 40:45-56.
20. Konig JFR, Klippel RA. 1963. The rat brain. Baltimore: Williams & Wilkins.
21. Kostrzewa RM, Gong L, Brus R. 1993. Serotonin (5-HT) systems mediate dopamine (DA) receptor supersensitivity. Acta Neurobiol Exp 53:31-41.
22. Krimer LS, Muly EC, Williams GV, Goldman-Rakic PS. 1998. Dopaminergic regulation of cerebral cortical microcirculation. Nat Neurosci 1:286-289.
23. Laruelle M. 1998. Imaging dopamine transmission in schizophrenia. A review and meta-analysis [In Process Citation]. Q J Nucl Med 42:211-221.
24. Lindvall O, Ingvar M, Stenevi U. 1981. Effects of methamphetamine on blood flow in the caudate-putamen after lesions of the nigrostriatal dopaminergic bundle in the rat. Brain Res 211:211-216.
25. Mandeville JB, Marota JJ, Kosofsky BE, Keltner JR, Weissleder R, Rosen BR, Weisskoff RM. 1998. Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn Reson Med 39:615-624.
26. Marshall JF, Ungerstedt U. 1977. Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: quantification using the rotational model. Eur J Pharmacol 41:361-367.
27. Mileson BE, Lewis MH, Mailman RB. 1991. Dopamine receptor 'supersensitivity' occurring without receptor up-regulation. Brain Res 561:1-10.
28. Mishra RK, Marshall AM, Varmuza SL. 1980. Supersensitivity in rat caudate nucleus: effects of 6-hydroxydopamine on the time course of dopamine receptor and cyclic AMP changes. Brain Res 200:47-57.
29. Nguyen TV, Kosofsky BE, Birnbaum R, Cohen BM, Hyman SE. 1992. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA 89:4270-4274.
30. Nordstrom AL, Farde L, Eriksson L, Halldin C. 1995. No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N- methylspiperone [see comments]. Psychiatry Res 61:67-83.
31. Perese DA, Ulman J, Viola J, Ewing SE, Bankiewicz KS. 1989. A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res 494:285-293.
32. Rioux L, Gaudin DP, Gagnon C, Di Paolo T, Bedard PJ. 1991. Decrease of behavioral and biochemical denervation supersensitivity of rat striatum by nigral transplants. Neuroscience 44:75-83.
33. Robertson HA, Paul ML, Moratalla R, Graybiel AM. 1991. Expression of the immediate early gene c-fos in basal ganglia: induction by dopaminergic drugs. Can J Neurol Sci 18:380-383.
34. Rubinstein M, Muschietti JP, Gershanik O, Flawia MM, Stefano FJ. 1990. Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice. J Pharmacol Exp Ther 252:810-816.
35. Sedvall G. 1992. The current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology 7:41-54.
36. Seeman P. 1992. Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on "the current status of PET scanning with respect to schizophrenia." Neuropsychopharmacology 7:55-57 (Discussion 73-55).
37. Seeman P, Niznik HB. 1990. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 4:2737-2744.
38. Seeman P, Guan HC, Van Tol HH. 1995. Schizophrenia: elevation of dopamine D4-like sites, using [3H]nemonapride and [125I]epidepride. Eur J Pharmacol 286:R3-5.
39. Sharp FR, Sagar SM, Swanson RA. 1993. Metabolic mapping with cellular resolution: c-fos vs. 2-deoxyglucose. Crit Rev Neurobiol 7:205-228.
40. Trugman JM. 1995. D1/D2 actions of dopaminergic drugs studied with [14C]-2-deoxyglucose autoradiography. Prog Neuropsychopharmacol Biol Psychiatry 19:795-810.
41. Trugman JM, James CL. 1992. Rapid development of dopaminergic supersensitivity in reserpine-treated rats demonstrated with 14C-2-deoxyglucose autoradiography. J Neurosci 12:2875-2879.
42. Trugman JM, James CL. 1993. D1 dopamine agonist and antagonist effects on regional cerebral glucose utilization in rats with intact dopaminergic innervation. Brain Res 607:270-274.
43. Trugman JM, Wooten GF. 1987. Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions. J Neurosci 7:2927-2935.
44. Ungerstedt U. 1971. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand (Suppl.) 367:69-93.
45. van Nguyen T, Paterson IA, Juorio AV, Greenshaw AJ, Boulton AA. 1989. Tryptamine receptors: neurochemical and electrophysiological evidence for postsynaptic and functional binding sites. Brain Res 476:85-93.
46. Villringer A, Rosen BR, Belliveau JW, Acerman JL, Lauffer RB, Buxton RB, Chao YS, Wedeen VJ, Brady TJ. 1988. Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn Reson Med 6:164-174.
47. Wong DF. 1992. PET studies of neuroreceptors in schizophrenia. Commentary on "the current status of PET scanning with respect to schizophrenia." Neuropsychopharmacology 7:69-72 (Discussion 73-65).
48. Zakzanis KK, Hansen KT. 1998. Dopamine D2 densities and the schizophrenic brain. Schizophr Res 32:201-206.
49. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. 1990. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13:290-296.